A retrospective study of venetoclax in combination with a hypomethylating agents in favorable-risk AML patients
Latest Information Update: 11 Jan 2021
At a glance
- Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 11 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology